Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Sells $589,200.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTXGet Free Report) Director Gary A. Lyons sold 40,000 shares of Travere Therapeutics stock in a transaction on Friday, October 4th. The shares were sold at an average price of $14.73, for a total value of $589,200.00. Following the sale, the director now directly owns 51,000 shares in the company, valued at $751,230. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Travere Therapeutics Price Performance

Shares of NASDAQ:TVTX opened at $15.21 on Wednesday. The company has a market capitalization of $1.16 billion, a PE ratio of -7.24 and a beta of 0.73. The company has a debt-to-equity ratio of 24.96, a quick ratio of 2.99 and a current ratio of 3.04. The stock has a fifty day moving average of $11.31 and a 200-day moving average of $8.78. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $15.61.

Travere Therapeutics (NASDAQ:TVTXGet Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%. The company had revenue of $54.12 million for the quarter, compared to analysts’ expectations of $49.50 million. As a group, equities analysts anticipate that Travere Therapeutics, Inc. will post -3.95 EPS for the current fiscal year.

Institutional Trading of Travere Therapeutics

Hedge funds have recently bought and sold shares of the company. EntryPoint Capital LLC purchased a new position in shares of Travere Therapeutics in the first quarter worth approximately $32,000. CWM LLC boosted its stake in Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after purchasing an additional 3,065 shares during the period. DRW Securities LLC purchased a new position in Travere Therapeutics during the 2nd quarter worth approximately $95,000. Forefront Analytics LLC raised its stake in Travere Therapeutics by 10.2% during the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after purchasing an additional 1,237 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Travere Therapeutics by 68.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 14,652 shares of the company’s stock worth $113,000 after buying an additional 5,962 shares during the period.

Analyst Ratings Changes

A number of research analysts have recently commented on TVTX shares. Citigroup lowered their price target on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a report on Friday, September 27th. Wedbush raised their target price on shares of Travere Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Barclays upped their price target on shares of Travere Therapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 1st. HC Wainwright lowered their price objective on shares of Travere Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, September 27th. Finally, JPMorgan Chase & Co. boosted their target price on Travere Therapeutics from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

View Our Latest Report on TVTX

About Travere Therapeutics

(Get Free Report)

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Further Reading

Insider Buying and Selling by Quarter for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.